Juvena Therapeutics uses AI-enabled discovery to find secreted proteins that restore tissue function, focusing first on neuromuscular disease. Lead asset JUV-161 is a muscle-regenerating biologic in Phase 1, with dosing completed across the multiple-ascending-dose cohorts. The company also has a research collaboration with Eli Lilly carrying more than $650 million in potential milestones. Headquartered in Redwood City, California.